Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for Stroke prevention in atrial fibrillation

Circulation

Volumn 127, Issue 22, 2013, Pages 2166-2176

  Wallentin, Lars ^a   Lopes, Renato D ^b   Hanna, Michael ^c   Thomas, Laine ^b   Hellkamp, Anne ^b   Nepal, Sunil ^d   Hylek, Elaine M ^e   Al Khatib, Sana M ^b   Alexander, John H ^b   Alings, Marco ^f   Amerena, John ^g   Ansell, Jack ^h   Aylward, Philip ⁱ   Bartunek, Jozef ^j   Commerford, Patrick ^k   De Caterina, Raffaele ^l   Erol, Cetin ^m   Harjola, Veli Pekka ⁿ   Held, Claes ^a   Horowitz, John D ^o   Huber, Kurt ^p   Husted, Steen ^q   Keltai, Matyas ^r   Lanas, Fernando ^s   Lisheng, Liu ^t   McMurray, John J V ^u   Oh, Byung Hee ^v   Rosenqvist, Mårten ^w   Ruzyllo, Witold ^x   Steg, Philippe Gabriel ^y   Vinereanu, Dragos ^z   Xavier, Denis ^aa   Granger, Christopher B ^b   more..

^a UPPSALA UNIVERSITY   (Sweden)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e BOSTON UNIVERSITY   (United States)

^f Working Group on Cardiovascular Research the Netherlands   (Netherlands)

^g DEAKIN UNIVERSITY   (Australia)

^h LENOX HILL HOSPITAL   (United States)

ⁱ FLINDERS UNIVERSITY   (Australia)

^j OLV HOSPITAL   (Belgium)

^k UNIVERSITY OF CAPE TOWN   (South Africa)

^l UNIVERSITY OF CHIETI   (Italy)

^m ANKARA UNIVERSITY   (Turkey)

ⁿ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^o UNIVERSITY OF ADELAIDE   (Australia)

^p WILHELMINEN HOSPITAL   (Austria)

^q REGIONAL HOSPITAL WEST JUTLAND   (Denmark)

^r SEMMELWEIS UNIVERSITY   (Hungary)

^s UNIVERSIDAD DE LA FRONTERA   (Chile)

^t National Center for Cardiovascular Diseases   (China)

^u UNIVERSITY OF GLASGOW   (United Kingdom)

^v Seoul National University Hospital   (South Korea)

^w DANDERYD HOSPITAL   (Sweden)

^x INSTITUTE OF CARDIOLOGY   (Poland)

^y UNIVERSITÉ PARIS DESCARTES   (France)

^z CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^aa ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

more..

Author keywords

Anticoagulation; Apixaban; Atrial Fibrillation; Bleeding; Stroke; Warfarin

Indexed keywords

APIXABAN; CREATININE; PLACEBO; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYSTOLIC DYSFUNCTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

ANTICOAGULATION; APIXABAN; ATRIAL FIBRILLATION; BLEEDING; STROKE; WARFARIN;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RISK FACTORS; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 84878535107     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.142158     Document Type: Article

References (24)

1. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867. (Pubitemid 351650486)
3. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005:CD001927.
4. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005;91:472-477. (Pubitemid 40432773)
5. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540-546. (Pubitemid 26272308)
6. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-1026. (Pubitemid 37087616)
7. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ. 2008;179:235-244.
8. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, Nalysnyk L. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004;126:1938-1945. (Pubitemid 39644002)
9. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167:239-245.
10. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
11. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029-2037.
12. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY Investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975-983.
13. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L; ARISTOTLE Investigators. Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159:331-339.
14. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
15. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-239. (Pubitemid 23069000)
16. van Leeuwen Y, Rombouts EK, Kruithof CJ, van der Meer FJ, Rosendaal FR. Improved control of oral anticoagulant dosing: a randomized controlled trial comparing two computer algorithms. J Thromb Haemost. 2007;5:1644-1649. (Pubitemid 47091405)
17. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11-17.
18. Pengo V, Pegoraro C, Cucchini U, Iliceto S. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis. 2006;21:73-77. (Pubitemid 43231132)
19. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129:1155-1166.
20. McBride D, Brüggenjürgen B, Roll S, Willich SN. Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice. J Thromb Thrombolysis. 2007;24:65-72. (Pubitemid 46838499)
21. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes. 2011;4:22-29.
22. Wieloch M, Själander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J. 2011;32:2282-2289.
23. Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691-1698. (Pubitemid 37468318)
24. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.